To include your compound in the COVID-19 Resource Center, submit it here.

Rituxan rituximab: Phase III data; marketed

ROCZ presented 3-year follow-up data from GELA, a European Phase III study in 339

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE